Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results

Rhea-AI Summary

Artivion (NYSE: AORT), a cardiac and vascular surgery company specializing in aortic disease, has scheduled its second quarter 2025 financial results release for Thursday, August 7, 2025, after market close.

The company will host a teleconference call and live webcast at 4:30 p.m. ET featuring CEO Pat Mackin, followed by a Q&A session. Participants can dial 862-298-0702 to join the call, with replay available at 877-660-6853 or 201-612-7415 using conference number 13754541.

The webcast and earnings press release will be accessible through the Investors section of www.artivion.com.

ATLANTA, July 24, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2025 financial results will be released on Thursday, August 7, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

To listen to the live teleconference, please dial 862-298-0702 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13754541. 

The live webcast and replay can be accessed on the Investors section of the Artivion website at www.artivion.com and by selecting Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investors section of the Artivion website.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Contacts:

Artivion Lance A. Berry Executive Vice President & Chief Financial Officer Phone: 770-419-3355

Gilmartin Group LLC Brian Johnston / Laine Morgan Phone: 332-895-3222 investors@artivion.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-release-date-and-teleconference-call-details-for-second-quarter-2025-financial-results-302513454.html

SOURCE Artivion, Inc.

FAQ

When will Artivion (AORT) release its Q2 2025 earnings?

Artivion will release its Q2 2025 financial results on Thursday, August 7, 2025 after the market closes.

How can I listen to Artivion's Q2 2025 earnings call?

You can dial 862-298-0702 before 4:30 p.m. ET on August 7, 2025, or access the live webcast through the Investors section at www.artivion.com.

Who will lead Artivion's Q2 2025 earnings call?

Pat Mackin, Chairman, President and Chief Executive Officer of Artivion, will lead the earnings call and Q&A session.

How can I access the replay of Artivion's Q2 2025 earnings call?

The replay will be available by calling 877-660-6853 or 201-612-7415 with conference number 13754541, or through the Investors section at www.artivion.com.